MSH2: Definition



Print this article

MSH2 is a protein that helps cells fix DNA mistakes. It is one of four mismatch repair proteins that pathologists test for in many cancers. When a tumor has lost MSH2, it cannot repair these mistakes properly. Loss of MSH2 can point to an inherited condition called Lynch syndrome. It can also mean the cancer is more likely to respond to immunotherapy.

This article explains what MSH2 does, how pathologists test for it, what retained and lost MSH2 results mean, and what happens after an abnormal result.

What does MSH2 do?

MSH2 works like a spell-checker for DNA. Every time a cell divides, it copies all of its DNA. Small copying mistakes happen. MSH2 finds these mistakes so other proteins can fix them.

MSH2 works with another protein, MSH6. Together, they spot the mistake. A second pair, MLH1 and PMS2, then helps repair it. These four proteins make up the mismatch repair system.

The MSH2 gene holds the instructions for making the MSH2 protein. MSH2 is a tumor suppressor gene. When both copies of the gene stop working, mistakes build up in the DNA. Over time, these mistakes can lead to cancer.

How do pathologists test for MSH2?

Pathologists test for MSH2 using immunohistochemistry. This test uses an antibody that sticks to the MSH2 protein in a thin slice of tumor tissue. Cells that contain MSH2 show brown staining in their nuclei.

Laboratories almost always test MSH2 together with MLH1, PMS2, and MSH6. Together, the four stains make up the mismatch repair, or MMR, panel. Laboratories commonly run this panel on colorectal and endometrial cancers. They also use it for many other cancers.

The pathologist compares the tumor cells with normal cells in the same slide. Normal cells, such as immune cells and the lining of blood vessels, should always stain. They act as a built-in check that the test worked.

What do MSH2 results mean?

Your report will usually describe MSH2 as retained or lost. Each laboratory may use slightly different words:

  • Retained, intact, or preserved. The tumor cells contain MSH2. This is the normal result. MSH2 is working in the tumor.
  • Lost, absent, or loss of expression. The tumor cells do not contain MSH2, while normal cells nearby do. The tumor is mismatch repair deficient, often written as dMMR.
  • Equivocal or indeterminate. The staining is weak or patchy, so the result is unclear. The pathologist may repeat the stain or order a different test.

When a tumor keeps all four MMR proteins, pathologists call it mismatch repair proficient (pMMR).

Why are MSH2 and MSH6 often lost together?

MSH2 and MSH6 are usually lost together because MSH6 needs MSH2 to stay stable. When MSH2 is missing, MSH6 also breaks down. Your report may therefore say “loss of MSH2 and MSH6.” This is one of the common abnormal MMR patterns.

The reverse is not true. A tumor can lose MSH6 alone while keeping MSH2.

What causes loss of MSH2?

Loss of MSH2 in a tumor has three main causes:

  • An inherited MSH2 change. A person is born with a change in one copy of the MSH2 gene. This causes Lynch syndrome. The tumor forms when the second copy is lost.
  • An inherited EPCAM change. EPCAM is a gene that sits next to MSH2. Some inherited deletions in EPCAM switch off MSH2. This also causes Lynch syndrome.
  • Changes only in the tumor. Sometimes both copies of MSH2 become damaged only in the tumor cells. Doctors call this a somatic change. It is not inherited and does not affect family members.

Loss of MSH2 is a strong signal to look for Lynch syndrome.

What happens if my tumor has lost MSH2?

Loss of MSH2 leads to two separate questions for your care team. One is about your family, and one is about treatment.

  • Genetic counseling and testing. Your doctor will usually refer you for genetic counseling. A blood or saliva test looks for an inherited change in MSH2 or EPCAM that causes Lynch syndrome. If the test finds one, your relatives can have testing for the same change.
  • Tumor sequencing. If genetic testing finds no inherited change, the laboratory may test the tumor itself with next-generation sequencing. Finding two MSH2 changes in the tumor supports a non-inherited cause.
  • Immunotherapy. Mismatch repair deficient tumors carry many DNA mistakes. These make the cancer easier for the immune system to recognize. In 2017, the FDA gave accelerated approval to pembrolizumab for advanced dMMR solid tumors that had grown after earlier treatment. This was the first FDA approval based on a tumor feature rather than where the cancer started.

The FDA has also approved other immunotherapy drugs for specific dMMR cancers. One example is dostarlimab, which received FDA approval in 2023 for advanced dMMR endometrial cancer that has grown after platinum chemotherapy. Approvals differ between countries. Your oncologist can explain which options apply to your cancer and stage.

Which cancers do laboratories test for MSH2?

MSH2 testing is most common in cancers linked to Lynch syndrome. These include:

  • Colorectal cancer. Many laboratories test every colorectal adenocarcinoma.
  • Endometrial cancer. Many laboratories test every endometrial carcinoma.
  • Other cancers. Testing is also done for stomach, small bowel, urinary tract, ovarian, and other cancers.
  • Sebaceous skin tumors. A sebaceous carcinoma or related skin tumor can be a sign of Muir-Torre syndrome, a form of Lynch syndrome.

Questions to ask your doctor

  • Did the laboratory test my tumor for all four mismatch repair proteins?
  • Was MSH2 retained or lost in my tumor?
  • Was MSH6 also lost?
  • Does this result mean I might have Lynch syndrome?
  • Should I have genetic counseling and germline testing?
  • Do my relatives need testing?
  • Will my tumor need next-generation sequencing?
  • Does this result change my treatment options, including immunotherapy?

Related articles on MyPathologyReport.com

A+ A A-
Was this article helpful?